These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 27234064)

  • 1. A phase I dose escalation trial of AXP107-11, a novel multi-component crystalline form of genistein, in combination with gemcitabine in chemotherapy-naive patients with unresectable pancreatic cancer.
    Löhr JM; Karimi M; Omazic B; Kartalis N; Verbeke CS; Berkenstam A; Frödin JE
    Pancreatology; 2016; 16(4):640-5. PubMed ID: 27234064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
    Amarantidis K; Houhouli K; Papatheodorou K; Miloussis A; Matthaios D; Chatzaki E; Lyrantzopoulos N; Tsaroucha A; Tentes A; Kakolyris S
    Oncol Res; 2006; 16(6):281-7. PubMed ID: 17476973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer.
    Aglietta M; Barone C; Sawyer MB; Moore MJ; Miller WH; Bagalà C; Colombi F; Cagnazzo C; Gioeni L; Wang E; Huang B; Fly KD; Leone F
    Ann Oncol; 2014 Sep; 25(9):1750-1755. PubMed ID: 24907635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.
    Duffy A; Kortmansky J; Schwartz GK; Capanu M; Puleio S; Minsky B; Saltz L; Kelsen DP; O'Reilly EM
    Ann Oncol; 2008 Jan; 19(1):86-91. PubMed ID: 17878176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer.
    Ueno H; Okusaka T; Ikeda M; Ishiguro Y; Morizane C; Matsubara J; Furuse J; Ishii H; Nagase M; Nakachi K
    Oncology; 2005; 69(5):421-7. PubMed ID: 16319514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of full-dose gemcitabine and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer.
    Uwagawa T; Misawa T; Sakamoto T; Ito R; Gocho T; Shiba H; Wakiyama S; Hirohara S; Sadaoka S; Yanaga K
    Ann Oncol; 2009 Feb; 20(2):239-43. PubMed ID: 18836085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors.
    Chan E; Chiorean EG; O'Dwyer PJ; Gabrail NY; Alcindor T; Potvin D; Chao R; Hurwitz H
    Cancer Chemother Pharmacol; 2018 Feb; 81(2):355-364. PubMed ID: 29238851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I/II study of combination chemotherapy with gemcitabine and 5-fluorouracil for advanced pancreatic cancer.
    Okusaka T; Ishii H; Funakoshi A; Ueno H; Furuse J; Sumii T
    Jpn J Clin Oncol; 2006 Sep; 36(9):557-63. PubMed ID: 16870696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial.
    Dragovich T; Huberman M; Von Hoff DD; Rowinsky EK; Nadler P; Wood D; Hamilton M; Hage G; Wolf J; Patnaik A
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):295-303. PubMed ID: 17149608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of antiangiogenic therapy using the mTOR-inhibitor everolimus and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer: a dose-finding study.
    Joka M; Boeck S; Zech CJ; Seufferlein T; Wichert Gv; Licht T; Krause A; Jauch KW; Heinemann V; Bruns CJ
    Anticancer Drugs; 2014 Oct; 25(9):1095-101. PubMed ID: 25029236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
    Goel A; Grossbard ML; Malamud S; Homel P; Dietrich M; Rodriguez T; Mirzoyev T; Kozuch P
    Anticancer Drugs; 2007 Mar; 18(3):263-71. PubMed ID: 17264757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.
    Rachamalla R; Malamud S; Grossbard ML; Mathew S; Dietrich M; Kozuch P
    Anticancer Drugs; 2004 Mar; 15(3):211-7. PubMed ID: 15014353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I trial of arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for unresectable advanced pancreatic cancer after vascular supply distribution via superselective embolization.
    Miyanishi K; Ishiwatari H; Hayashi T; Takahashi M; Kawano Y; Takada K; Ihara H; Okuda T; Takanashi K; Takahashi S; Sato Y; Matsunaga T; Homma H; Kato J; Niitsu Y
    Jpn J Clin Oncol; 2008 Apr; 38(4):268-74. PubMed ID: 18375446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 1 study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer.
    Sun W; Hewitt MR; Theobald MR; Hershock D; Haller DG
    Cancer; 2007 Dec; 110(12):2768-74. PubMed ID: 17932893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma.
    Chiorean EG; Dragovich T; Hamm J; Langmuir VK; Kroll S; Jung DT; Colowick AB; Tidmarsh GF; Loehrer PJ
    Cancer Chemother Pharmacol; 2008 May; 61(6):1019-26. PubMed ID: 17661038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weekly gemcitabine and 24-hour infusional 5-fluorouracil in advanced pancreatic cancer: a phase I-II study.
    Barone C; Cassano A; Corsi DC; Pozzo C; Longo R; Schinzari G; Quirino M; Battelli C; Basso M
    Oncology; 2003; 64(2):139-45. PubMed ID: 12566911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of fixed dose rate infusion gemcitabine with gefitinib in patients with pancreatic carcinoma.
    Carneiro BA; Brand RE; Fine E; Knop RH; Khandekar JD; Uhlig W; Locker GY
    Cancer Invest; 2007 Aug; 25(5):366-71. PubMed ID: 17661212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer.
    Jang J; Kim HK; Cho BC; Lee KH; Yun HJ; Woo IS; Song HS; Ryoo HM; Kim CH; Sun DS; Shin JW
    Cancer Chemother Pharmacol; 2017 May; 79(5):873-880. PubMed ID: 28341958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors.
    Mettu NB; Niedzwiecki D; Rushing C; Nixon AB; Jia J; Haley S; Honeycutt W; Hurwitz H; Bendell JC; Uronis H
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1025-1035. PubMed ID: 30895346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 1 study of gemcitabine/nab-paclitaxel/S-1 (GAS) combination neoadjuvant chemotherapy for patients with locally advanced pancreatic adenocarcinoma.
    Kondo N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakagawa N; Takahashi S; Ohge H; Sueda T
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):775-781. PubMed ID: 28293715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.